AbbVie Inc. (NYSE:ABBV) saw unusually large options trading activity on Wednesday. Stock investors acquired 278 put options on the company. This is an increase of 121% compared to the average daily volume of 126 put options.
In related news, SVP Azita Saleki-Gerhardt sold 8,300 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $85.02, for a total transaction of $705,666.00. Following the completion of the sale, the senior vice president now directly owns 93,099 shares of the company’s stock, valued at $7,915,276.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Chairman Richard A. Gonzalez sold 193,131 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $71.00, for a total transaction of $13,712,301.00. Following the sale, the chairman now directly owns 469,623 shares of the company’s stock, valued at $33,343,233. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 226,430 shares of company stock valued at $16,664,544. Company insiders own 0.23% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Waldron LP lifted its stake in AbbVie by 31.0% during the first quarter. Waldron LP now owns 6,984 shares of the company’s stock worth $446,000 after purchasing an additional 1,653 shares in the last quarter. Palo Capital Inc. acquired a new stake in shares of AbbVie in the first quarter valued at $212,000. Schmidt P J Investment Management Inc. raised its stake in shares of AbbVie by 2.6% in the first quarter. Schmidt P J Investment Management Inc. now owns 88,635 shares of the company’s stock valued at $5,775,000 after acquiring an additional 2,238 shares in the last quarter. Meyer Handelman Co. raised its stake in shares of AbbVie by 6.4% in the first quarter. Meyer Handelman Co. now owns 95,216 shares of the company’s stock valued at $6,204,000 after acquiring an additional 5,766 shares in the last quarter. Finally, Hamlin Capital Management LLC increased its holdings in AbbVie by 14.6% in the first quarter. Hamlin Capital Management LLC now owns 1,244,866 shares of the company’s stock valued at $81,115,000 after buying an additional 158,763 shares during the last quarter. Hedge funds and other institutional investors own 68.49% of the company’s stock.
Shares of AbbVie (ABBV) opened at $92.31 on Friday. The firm has a market capitalization of $145.09 billion, a PE ratio of 17.14, a price-to-earnings-growth ratio of 1.24 and a beta of 1.51. The company has a current ratio of 1.38, a quick ratio of 1.25 and a debt-to-equity ratio of 5.63.
AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 164.66% and a net margin of 24.38%. The firm had revenue of $7 billion during the quarter, compared to analyst estimates of $7 billion. During the same quarter in the previous year, the business earned $1.21 EPS. AbbVie’s revenue for the quarter was up 8.8% compared to the same quarter last year. equities analysts predict that AbbVie will post 5.55 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a $0.71 dividend. The ex-dividend date is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.08%. AbbVie’s dividend payout ratio is 62.29%.
ABBV has been the topic of a number of recent analyst reports. BidaskClub upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 6th. Evercore ISI restated an “outperform” rating and set a $100.00 price target (up previously from $95.00) on shares of AbbVie in a report on Saturday, September 30th. Credit Suisse Group restated a “neutral” rating and set a $74.00 price target (up previously from $65.00) on shares of AbbVie in a report on Thursday, July 20th. Barclays PLC restated a “hold” rating and set a $68.00 price target on shares of AbbVie in a report on Thursday, September 28th. Finally, Cowen and Company upgraded shares of AbbVie from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $91.17 to $105.00 in a report on Wednesday, October 11th. Eight analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $93.68.
ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2017/11/04/traders-buy-large-volume-of-put-options-on-abbvie-abbv.html.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
What are top analysts saying about AbbVie Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AbbVie Inc. and related companies.